Histone Deacetylase Inhibitors as Therapeutics for Endometriosis

Xin Li; Xishi Liu; Sun-Wei Guo


Expert Rev of Obstet Gynecol. 2012;7(5):451-466. 

In This Article

Five-year View

We envision that in the next 5 years more epigenetic aberrations in endometriosis will be documented, catalogued and delineated. More specifically, we may see the difference in epigenetic aberrations between endometriosis that causes pain and infertility. We will have a better understanding as to which HDACs are aberrantly expressed in ovarian endometriomas versus peritoneal endometriosis versus deep infiltrating endometriosis. We may also know which types of HDACIs are better at treating endometriosis, not only in the sense of efficacy but also in the sense of causing fewer and/or milder, more tolerable side effects. As we have a better grasp of the endometrial epigenome and its response to steroid hormones as well as all epigenetic aberrations in endometriosis, we may also find ways to treat endometriosis-caused infertility.

Diagnostic and prognostic tools and procedures based on epigenetic aberrations may also emerge. Epigenetics-based biomarkers that help to monitor the treatment effect may also be developed.

We also envision that future studies will document and catalogue aberrations of various readers, writers and effectors of histone modifications in endometriosis,[44] attempt to delineate their roles in the genesis and development of endometriosis, and discover methods for intervention or even prevention.